Phase 2 study of NG101 for acute spinal cord injury published in The Lancet Neurology

NovaGo Therapeutics AG announced that its academic collaboration partners — the Nogo-A Inhibition in Spinal Cord Injury Study Group (NISCI) — published the results for the investigation of NG101 in acute spinal cord injury patients in The Lancet Neurology.

NovaGo’s founder and CSO Prof. Martin Schwab originally initiated the formation of the large multinational NISCI consortium (14 member institutions) in 2015 in collaboration with Prof. Armin Curt (Balgrist University Hospital, Zurich) and Prof. Norbert Weidner (Heidelberg University Hospital). It was financed by the EU’s Horizon 2020 programme, the Swiss State Secretariat for Education, Research and Innovation, the Swiss Paraplegic Foundation, the Wings for Life foundation and others.

The NISCI Phase 2 study evaluated the efficacy and safety of an anti-Nogo-A antibody in 129 acute spinal cord injury patients in a multicenter, multi-country, placebo-controlled clinical trial.

“We are excited to see early signs of disease-modifying effects for the treatment of acute spinal cord injuries and applaud the team for their remarkable achievements,” said Stefan Moese, CEO of NovaGo.